The Short Case on $IBRX Has a Problem, and It Is Showing in the Tape

Listen: hear this article read aloud (about 2 min).

ImmunityBio, Inc. Common Stock keeps going up and the short keeps pressing. One of those has to give.

$IBRX sits at $7.35, $3.27 below its 20-day high of $10.62 and $0.40 above its 20-day low of $7.75.

My read: neutral, waiting on confirmation. I want confirmation before I call a direction.

The shorts have a problem

Against its own 60-session range, $IBRX is 32.0% below the high of $10.81 (Oct 5) and 1.1% above the low of $7.43 (Aug 14). $IBRX closed higher in 5 of its last 9 sessions.

Volume over the last five sessions averaged 0.7x the twenty sessions before them.

The largest one-day move in the past twenty sessions was +10.5% on Oct 27. 56% of IBRX's off-exchange volume printed as short sales (FINRA daily short volume), against a normal 60%. Days to cover: 7.2. Every short in the name needs 7.2 full days of normal volume to get out.

What I make of it: a crowded short matters only if the stock stops falling, and then covering becomes buying. Whether that starts here is the whole question.

Who is positioned for what

Off-exchange trading: NORMAL: $376K block at $7.51, +22% yesterday's biggest. Biggest single off-exchange print: 50,000 shares at $7.51, about $376K, on a downtick (seller hit). A print that size is one order being crossed away from the public book, not a crowd of small trades.

In options, dealers long gamma, call wall $9.00, put wall $7.00, gamma flip near $7.00, hedge pressure 0% of an average day's volume. Days to cover 7.2, 122.9M shares short, short interest -0.9% since the last report. Squeeze risk 24 of 100; shorts pressing 55 of 100.

Across the broader market, the read is Neutral (bias +12).

Sentiment readings show bullish (60 of 100).

What I make of it: the data agrees with itself more than it argues, and that counts for something. It still falls short of proof.

The bull case

• Short squeeze setup with a measured path to $8.94

The bear case

• Backdrop: Neutral (bias +12)
• High short volume is routine in liquid names

What I think traders are overlooking

What I think traders are overlooking is the volume. Price can drift to a level on almost nothing, and what it does there needs real participation. Without it, a break is easy to fade.

None of that is visible in the candles.

What happens next, and when I'm out

If $IBRX posts a close above the recent high on rising volume and volume expands, I think $8.94 becomes the next serious test. Under $6.62, I'm wrong.

The honest objection is that short volume is not a short position. A high ratio is routine in liquid names, and sometimes the shorts are simply right.

Clear the level on volume and I'm interested. Fail below the line and I'm out of the idea.

Kill switch

Any one of these and the thesis is over, no averaging down, no renaming it.

• A close through $6.62.
• Selling absorbs the buying at a key level and price loses it on volume.
• Order flow reverses: the sweeps and blocks turn to the other side.
• A scheduled event changes the picture before the trigger is reached.

My read

I'm neutral until the stock gives me a reason. The level is clear and so is the line that proves me wrong, so there's nothing to do until one of them gets tested.

Desk record. 32 of 184 scenario targets traded before their invalidation (17%), 101 stopped out, 51 ran out of time, average outcome +0.09% per piece. Past pieces say nothing about this one.

The desk's scenario leans bullish. Bull or bear, the kill switch above is what keeps either view honest.

Sources and further reading: SEC EDGAR filings for IBRX · FINRA daily short sale volume files · Nasdaq short interest: IBRX · Cboe options quotes: IBRX · ImmunityBio, Inc. Common Stock investor site · IBRX quote, chart and data on StockMarketLoop.

Data as of Nov 9, 8:48 AM ET: options positioning, FINRA short volume, the off-exchange trade record, the structure map, SEC filings and the ticker's headlines. Vaughn McNair (Grandmaster-Obi) and Making Easy Money may hold or trade positions in the names discussed. This is speculation and education, not financial advice.